Gliomas are the most common primary tumors of the central nervous system, accounting for 27% of brain tumors and 80% of malignant brain tumors. More than half of malignant primary brain tumors are glioblastomas with expected media survival around 56 weeks. Recently, PD-1/PD-L1 antibody adjuvant immunotherapy gave new hope for current glioblastoma patients. And chimeric antigen receptor (CAR) engineered T cells and NK cells are becoming a novel therapeutic strategy for the treatment of glioblastomas. The microglia-mediated immune-resistance still holds another side of this issue. Therefore, an urgent need to dig deeper within any aspect of immuno-oncology remains.
In recent years, the development of gene sequencing technologies, such as single-cell sequencing and ATAC sequencing, provided a deeper vision of gene expression landscape at the single-cell level. Novel therapeutics aim at enhancing the activity of CD8 T cells and suppressing the immuno-suppressive environment of cancer. Furthermore, novel nano-therapeutic systems can cross the blood-brain-barrier to mimic the cytotoxicity of CD8 positive T cells by delivering granzyme B nanoparticles. These new therapeutics are currently used to target subcutaneous cancers and could be potentially used in brain tumors.
This Research Topic focuses on every aspect of immunology in glioblastoma, including but not limited to, novel technology and bioinformatics in sequencing and proteomics, nanotechnology for brain tumors and immuno-modulation, novel mechanisms of immune-resistance, molecular markers,surgical technology, drug treatment, chemotherapy and CAR-T cell therapy of glioblastoma. The purpose of this Research Topic is to focus on the state-of-art in immune-oncology and to bridge immunology and the therapeutics of glioblastoma.
We welcome authors to submit Original Research, Review, and Perspective articles focusing on:
1. Novel technology and bioinformatics in sequencing and proteomics, single-cell sequencing and ATAC-sequencing in the expression landscape of immune cells in glioblastoma
2. The bioinformatics, molecular markers, subtyping, and predictive factors associated with immunotherapy of glioblastoma
3. Nanotechnology for the treatment of glioblastoma and immuno-modulation
4. Chemotherapy, radiotherapy, adjuvant therapeutics with immuno-check point blockage and CAR-T therapy are warmly welcome
5. Novel mechanisms of immune resistance to glioblastoma
Gliomas are the most common primary tumors of the central nervous system, accounting for 27% of brain tumors and 80% of malignant brain tumors. More than half of malignant primary brain tumors are glioblastomas with expected media survival around 56 weeks. Recently, PD-1/PD-L1 antibody adjuvant immunotherapy gave new hope for current glioblastoma patients. And chimeric antigen receptor (CAR) engineered T cells and NK cells are becoming a novel therapeutic strategy for the treatment of glioblastomas. The microglia-mediated immune-resistance still holds another side of this issue. Therefore, an urgent need to dig deeper within any aspect of immuno-oncology remains.
In recent years, the development of gene sequencing technologies, such as single-cell sequencing and ATAC sequencing, provided a deeper vision of gene expression landscape at the single-cell level. Novel therapeutics aim at enhancing the activity of CD8 T cells and suppressing the immuno-suppressive environment of cancer. Furthermore, novel nano-therapeutic systems can cross the blood-brain-barrier to mimic the cytotoxicity of CD8 positive T cells by delivering granzyme B nanoparticles. These new therapeutics are currently used to target subcutaneous cancers and could be potentially used in brain tumors.
This Research Topic focuses on every aspect of immunology in glioblastoma, including but not limited to, novel technology and bioinformatics in sequencing and proteomics, nanotechnology for brain tumors and immuno-modulation, novel mechanisms of immune-resistance, molecular markers,surgical technology, drug treatment, chemotherapy and CAR-T cell therapy of glioblastoma. The purpose of this Research Topic is to focus on the state-of-art in immune-oncology and to bridge immunology and the therapeutics of glioblastoma.
We welcome authors to submit Original Research, Review, and Perspective articles focusing on:
1. Novel technology and bioinformatics in sequencing and proteomics, single-cell sequencing and ATAC-sequencing in the expression landscape of immune cells in glioblastoma
2. The bioinformatics, molecular markers, subtyping, and predictive factors associated with immunotherapy of glioblastoma
3. Nanotechnology for the treatment of glioblastoma and immuno-modulation
4. Chemotherapy, radiotherapy, adjuvant therapeutics with immuno-check point blockage and CAR-T therapy are warmly welcome
5. Novel mechanisms of immune resistance to glioblastoma
